Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $13.66 and traded as low as $13.40. Enanta Pharmaceuticals shares last traded at $13.83, with a volume of 141,517 shares.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on ENTA. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.29.
View Our Latest Stock Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Stock Up 1.6%
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. The company had revenue of $17.16 million during the quarter, compared to the consensus estimate of $17.03 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -1.98 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its position in shares of Enanta Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after purchasing an additional 54,396 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after purchasing an additional 650,000 shares in the last quarter. Krensavage Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares in the last quarter. Millennium Management LLC lifted its position in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares in the last quarter. Finally, Spruce Street Capital LP lifted its position in shares of Enanta Pharmaceuticals by 139.3% during the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock worth $11,779,000 after purchasing an additional 542,911 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s directâacting antiviral regimens.
Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.
Featured Stories
- Five stocks we like better than Enanta Pharmaceuticals
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
